5-amino-1,2-dihydroisoquinolin-1-one

Research use only, not for human use.

5-aminoisoquinolin-1(2H)-one is the inhibitor of calf thymus PARP1.

5-aminoisoquinolin-1(2H)-one is the inhibitor of calf thymus PARP1.

5-AIQ (5000 μg) significantly reduces the number of colonies of TA 98 without metabolic activation, and TA 98 and TA 1537 with metabolic activation.

5-AIQ (150 and 250 mg/kg; p.o.; once) possess no significantly genotoxic in vivo system by micronucleus test.5-AIQ (3 mg/kg; p.o.; 5 min prior to onset of liver ischemia) reduces the tissue injury associated with ischemia-reperfusion of the liver. Animal Model:Male mice Dosage:150 and 250 mg/kg Administration:Oral administration; 150 and 250 mg/kg; once Result:Showed no increase of micronucleated polychromatic erythrocytes (MNPCE) in both 24 h and 48 h after both 125 and 250 mg/kg duration exposure as compared to the corresponding control.Animal Model:Anesthetised male Wistar rats with liver ischemia (for 30 minutes) and reperfusion (for 2 hours) Dosage:3 mg/kg Administration:Intravenous injection; 3 mg/kg; 5 min prior to onset of liver ischemiaResult:Reduced PARP activation and showed less staining for ICAM-1.

——

Cell Cycle/DNA Damage

PARP

TRPV1

——

——

93117-08-9

160.176

C9H8N2O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (624.34 mM)

Nc1cccc2c(O)nccc12

——

(-20℃)

With Ice Pack

≥ 2 years